Intelligent Bio Solutions Inc. (INBS)
| Market Cap | 5.14M -42.0% |
| Revenue (ttm) | 3.58M +18.1% |
| Net Income | -11.29M |
| EPS | -14.67 |
| Shares Out | 2.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,448 |
| Open | 2.340 |
| Previous Close | 2.290 |
| Day's Range | 2.290 - 2.370 |
| 52-Week Range | 2.270 - 24.900 |
| Beta | 4.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 22, 2026 |
About INBS
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporate... [Read more]
Financial Performance
In fiscal year 2025, Intelligent Bio Solutions's revenue was $3.05 million, a decrease of -1.90% compared to the previous year's $3.11 million. Losses were -$10.57 million, 4.06% more than in 2024.
Financial StatementsNews
Intelligent Bio Solutions announces launch of validation study for IFDSS
Intelligent Bio Solutions (INBS) announced the launch of a validation study aimed at significantly reducing the analysis time of its Intelligent Fingerprinting Drug Screening System, IFDSS. The study ...
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes
Intelligent Bio Solutions announces completion of penetrating testing
Intelligent Bio Solutions (INBS) announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabilities, verified the...
Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified
INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission INBS implements enhanced security architecture to protect test int...
Intelligent Bio completes initial drug screening system clinical cut-off study
Intelligent Bio Solutions (INBS) announced the successful completion of its initial clinical cut-off study supporting the company’s FDA 510(k) submission for U.S. market clearance of its Intelligent F...
Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability,...
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing s...
Intelligent Bio Solutions manufactures, ships first readers with new partner
Intelligent Bio Solutions (INBS) announced the receipt and deployment of the first shipment of Intelligent Fingerprinting Drug Screening Readers manufactured under its new strategic manufacturing part...
Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026
Intelligent Bio Solutions announces partnership with Bouygues UK
Intelligent Bio Solutions (INBS) announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi-billion-dollar global construction firm with 35,600 employees, for the deploym...
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS's fingerprint drug testing t...
Intelligent Bio Solutions reports Q2 EPS ($2.82) vs. ($4.96) last year
Reports Q2 revenue $896,774 vs. $607,494 last year. “Our second quarter figures demonstrate consistency and solid progress across our business,” said Harry Simeonidis, President and CEO of INBS. “Read...
Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year
First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum G...
Intelligent Bio Solutions reports preliminary Q2 revenue $2.01M
“We are very pleased with our expected results, showing strong second-quarter performance and reader sales more than doubling year-over-year,” said Harry Simeonidis, President and CEO at Intelligent B...
Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more tha...
Intelligent Bio Solutions initiates additional studies for FDA 510k submission
Intelligent Bio Solutions (INBS) announced the commencement of its clinical study program to support its new FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Scre...
Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
Clinical studies designed to support FDA clearance and planned commercial launch into the world's largest drug screening market Company anticipates full data analysis by the end of March 2026; data t...
Intelligent Bio Solutions files to sell 6.9M shares of common stock for holders
17:02 EST Intelligent Bio Solutions (INBS) files to sell 6.9M shares of common stock for holders
Why Did Intelligent Bio Solutions (INBS) Stock Surge 76% Today?
After diving over 17% on January 2, shares in biopharma company Intelligent Bio Solutions ($INBS) are back with a rally, surging as high as 76% on Monday afternoon. While there…
Intelligent Bio Solutions Inc trading resumes
09:35 EST Intelligent Bio Solutions (INBS) Inc trading resumes
Intelligent Bio Solutions Inc trading halted, volatility trading pause
09:30 EST Intelligent Bio Solutions (INBS) Inc trading halted, volatility trading pause
Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing so...
Why Is Intelligent Bio Solutions Stock (INBS) Down Today?
Intelligent Bio Solutions stock was down after it announced a private placement.
Intelligent Bio Solutions prices $10M private placement
Intelligent Bio Solutions (INBS) announced that it entered into a securities purchase agreement with two healthcare focused institutional investors to issue, in a private placement priced at-the-marke...
Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing so...